Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Multisite Validation of a Venous Thrombosis Risk Model in Critically Ill Children Through the CHAT Consortium

Julie Jaffray, Brian R Branchford, Maua Mosha Alleyne, Ernest Amankwah, E. Vincent S. Faustino, Neil A Zakai, Anthony A. Sochet, Amy Stillings, Emily Krava, Guy Young, Neil A Goldenberg

Blood blood.2025029841.

https://doi.org/10.1182/blood.2025029841

Published: 2025

Includes: Supplemental data

Journal Articles

New fitusiran 10 mg dose increases proportion of people with hemophilia within target antithrombin range of 15–35%

Guy Young, Alok Srivastava, Marek Demissie, Malidi Ahamadi, Abhimanyu Yarramaneni, Yuqian Shen, Steven Pipe

Blood (2025) 146 (Supplement 1): 6615.

https://doi.org/10.1182/blood-2025-6615

Published: 2025

Journal Articles

Bleeding rates in patients with congenital hemophilia B without inhibitors: A systematic review and meta-analysis

Kristina Lindsley, Arianna Nevo, Carmine Colavecchia, Lisa Wilcox, Priya Patel, Carlos Estevez, Cynthia Khanji, Jennifer Uyei, Steven Pipe, Guy Young

Blood (2025) 146 (Supplement 1): 6613.

https://doi.org/10.1182/blood-2025-6613

Published: 2025

Journal Articles

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

Guy Young, Chanchala Kaddi, Shariq Ali, Lila-Sabrina Fetita, Ekta Seth Chhabra, Marek Demissie, Sheng-Chieh Chou

Blood (2025) 146 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2025-3076

Published: 2025

Journal Articles

In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay

Sibgha Zaheer, Elizabeth Marquez Casas, Guy Young

Blood (2025) 146 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2025-1295

Published: 2025

Journal Articles

Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran

Steven Pipe, Tienan Zhu, Kaan Kavakli, Stephanie P'ng, Chur-Woo You, Inga Hegemann, Gili Kenet, Teh-Liane Khoo, Margarita Timofeeva, Guy Young, Laurel Menapace, Abhimanyu Yarramaneni, Yuqian Shen, Umer Khan, Sandra Casiano, Arta Subagiarta, Julian Zorrilla

Blood (2025) 146 (Supplement 1): 4850.

https://doi.org/10.1182/blood-2025-4850

Published: 2025

Journal Articles

Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)

Sibgha Zaheer, Elizabeth Marquez Casas, Shariq Ali, Erica Ma, Yueh-Yun Chi, Guy Young

Blood (2025) 146 (Supplement 1): 4849.

https://doi.org/10.1182/blood-2025-4849

Published: 2025

Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen Tran, Chur-Woo You, Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet

Blood (2025) 145 (25): 2966–2977.

https://doi.org/10.1182/blood.2024027008

Published: 2025

Includes: Supplemental data

Journal Articles

Assessment of the Combined Effects of Emicizumab and Fitusiran with in Vitro Spiking of Simulated Fitusiran (using anti-thrombin antibody) into Plasma from Hemophilia a Patients on Emicizumab

Sibgha Zaheer, Elizabeth Marquez Casas, Myew-Ling Toh, Guy Young

Blood (2024) 144 (Supplement 1): 132.

https://doi.org/10.1182/blood-2024-206336

Published: 2024

Journal Articles

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Guy Young, Katherine Eakle, Elise Lim, Michael Wang

Blood (2024) 144 (Supplement 1): 2589.

https://doi.org/10.1182/blood-2024-193816

Published: 2024

Journal Articles

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Tadashi Matsushita, Pratima Chowdary, Atanas Mitkov Banchev, Kaan Kavakli, Johanna A. Kremer Hovinga, Jerzy Windyga, Víctor Jiménez-Yuste, Julien Bovet, Llenalia María García Fernández, Guy Young

Blood (2024) 144 (Supplement 1): 718.

https://doi.org/10.1182/blood-2024-198617

Published: 2024

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

How I treat pediatric venous thromboembolism in the DOAC era

Rukhmi V. Bhat, Guy Young, Anjali A. Sharathkumar

Blood (2024) 143 (5): 389–403.

https://doi.org/10.1182/blood.2022018966

Published: 2024

Journal Articles

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Giancarlo Castaman, Aby Abraham, Pantep Angchaisuksiri, Laura Villarreal Martinez, Keiji Nogami, Jameela Sathar, Chunduo Shen, Jay Jay Thaung Zaw, Guy Young

Blood (2023) 142 (Supplement 1): 284.

https://doi.org/10.1182/blood-2023-180790

Published: 2023

Journal Articles

Inflammation Sub-Group Analysis in Pediatric HA-VTE Cases: A Report from the Children's Hospital Acquired Thrombosis Registry (CHAT) Registry

Taylor Harp, Kailey Proctor, Maua Mosha, Allaura Cox, Julie Jaffray, Amy Stillings, Emily Krava, Ernest K Amankwah, E. Vincent Faustino, Neil A. Zakai, Guy Young, Neil Goldenberg, Brian R. Branchford

Blood (2023) 142 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2023-190491

Published: 2023

Journal Articles

Multicenter Study of a Risk Prediction Model for Critically Ill Children at High-Risk for Hospital-Acquired Venous Thromboembolism: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium

Julie Jaffray, Maua Mosha, Brian R. Branchford, Ernest K Amankwah, E. Vincent Faustino, Emily Krava, Amy Stillings, Guy Young, Neil Goldenberg

Blood (2023) 142 (Supplement 1): 809.

https://doi.org/10.1182/blood-2023-187395

Published: 2023

Journal Articles

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Robert Klamroth, Robert F Sidonio, Jr., Yesim Dargaud, Víctor Jiménez-Yuste, Rolf Ljung, Guy Young, Pratima Chowdary

Blood (2023) 142 (Supplement 1): 1255.

https://doi.org/10.1182/blood-2023-181725

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

Guy Young, Vinod V. Balasa, Jonathan C. Roberts, Andrew Frick, Ali G Mokdad, Jorge Caicedo

Blood (2023) 142 (Supplement 1): 3742.

https://doi.org/10.1182/blood-2023-178042

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multisite Validation of a Venous Thrombosis Risk Model in Critically Ill Children Through the CHAT Consortium

New fitusiran 10 mg dose increases proportion of people with hemophilia within target antithrombin range of 15–35%

Bleeding rates in patients with congenital hemophilia B without inhibitors: A systematic review and meta-analysis

Evaluating the safety and tolerability of switching from emicizumab to fitusiran prophylaxis in adult males with severe hemophilia A, with or without inhibitors: SWITCH study, a trial in progress

In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay

Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran

Comparison of hemosil and innovance antithrombin assays using Hemophilia A plasma and antithrombin lowering (to mimic fitusiran)

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Assessment of the Combined Effects of Emicizumab and Fitusiran with in Vitro Spiking of Simulated Fitusiran (using anti-thrombin antibody) into Plasma from Hemophilia a Patients on Emicizumab

FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A

Safety and Efficacy of Mim8 Prophylaxis Administered Once Every Two Weeks for Patients with Hemophilia A with or without Inhibitors: Interim Analysis of the FRONTIER4 Open-Label Extension Study

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

How I treat pediatric venous thromboembolism in the DOAC era

The Effect of Concizumab Prophylaxis on Target Joints, Resolution and Joint Bleeds in Patients With Hemophilia A or B With or Without Inhibitors in Phase 3 Clinical Trials

Inflammation Sub-Group Analysis in Pediatric HA-VTE Cases: A Report from the Children's Hospital Acquired Thrombosis Registry (CHAT) Registry

Multicenter Study of a Risk Prediction Model for Critically Ill Children at High-Risk for Hospital-Acquired Venous Thromboembolism: Findings from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium

Design of an Observational Study (PROVE) to Assess the Long-Term Effects of Prophylaxis with Simoctocog Alfa or Emicizumab on Joint and Bone Health in Hemophilia a Patients

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Identifying Ideal Individuals for PK-Guided Dosing; Recreational Risks and Elevated Breakthrough Bleeding

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only